Welcome to our dedicated page for Atricure news (Ticker: ATRC), a resource for investors and traders seeking the latest updates and insights on Atricure stock.
AtriCure, Inc. (symbol: ATRC) is a leading provider of cutting-edge medical technologies aimed at treating atrial fibrillation (Afib) and related conditions. With over 33 million people affected by Afib globally, AtriCure stands at the forefront of developing innovative solutions to combat this prevalent health issue. Electrophysiologists and cardiothoracic surgeons around the world rely on AtriCure's products to reduce complications associated with Afib.
The company's flagship product, the Isolator® Synergy™ Ablation System, is notably the first and only device approved by the FDA for the treatment of persistent Afib. Additionally, the AtriClip Left Atrial Appendage Exclusion System holds the title of the most widely sold LAA management device globally, with over 100,000 units implanted to date.
AtriCure's diverse product line includes solutions for Cryoablation, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, among others. They also offer a range of minimally invasive ablation devices and access tools catering to the increasing demand for less invasive cardiac and thoracic surgeries. Their products are distributed to medical centers through a combination of a direct sales force and a network of distributors.
Geographically, the majority of AtriCure's revenue is generated from the United States. The company continues to expand its impact through ongoing projects, research, and partnerships aimed at improving patient outcomes and advancing the field of cardiac surgery.
For more detailed information about AtriCure's latest developments, visit their official website at AtriCure.com or follow them on Twitter @AtriCure.
AtriCure, Inc. (Nasdaq: ATRC) reported its fourth quarter and full year 2020 financial results, revealing a 5.9% decline in Q4 revenue to $57.7 million, with a full year revenue decrease of 10.5% to $206.5 million, attributed to COVID-19 impacts on surgical procedures. Gross profit in Q4 was $42.4 million with a margin of 73.5%. Adjusted EBITDA improved to a positive $1.7 million in Q4. For 2021, revenue guidance is projected at $250 million, with anticipated adjusted EBITDA losses of $10 million. The first quarter forecast revenue ranges from $55 million to $57 million.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), has announced its participation in the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 8:00 a.m. ET. The event will feature a live and archived audio webcast available on the company's website. AtriCure’s innovative technologies, including the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System, are widely utilized for Afib treatment, impacting over 33 million individuals globally. For further details, visit AtriCure.com.
AtriCure, Inc. (Nasdaq: ATRC) will release its fourth quarter and full year 2020 financial results on February 23, 2021.
The company will host a conference call at 4:30 p.m. ET on the same day to discuss these results. Interested parties can join the call via phone or listen to a live audio webcast on AtriCure's corporate website. AtriCure specializes in innovative technologies for treating atrial fibrillation (Afib) and left atrial appendage (LAA) management, offering FDA-approved devices that lead the market.
AtriCure, Inc. (ATRC) announced its preliminary financial results for Q4 and full-year 2020, reporting revenue of approximately $57.7 million in Q4, a 6% decline year-over-year, and about $206.5 million for the full year, down 11%. The company acknowledged the impact of COVID-19 on procedure volumes but noted a sequential revenue increase of 5% from Q3 2020. AtriCure emphasized its strong financial position and strategic progress, highlighting upcoming catalysts for growth in 2021, including new procedures and clinical trial data.
AtriCure, Inc. (Nasdaq: ATRC) has announced FDA 510(k) clearance for expanded labeling claims of its cryo nerve block therapy, now including treatment for adolescent patients aged 12-21. The cryoICE® and cryoSPHERE™ probes provide effective pain management post-surgery, particularly for procedures like the Nuss procedure for pectus excavatum. Collaborating with the UCSF-Stanford Pediatric Device Consortium, AtriCure aims to innovate pediatric medical devices efficiently. This expansion could enhance recovery experiences for younger patients undergoing invasive chest wall surgeries.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in the 39th Annual J.P. Morgan Healthcare Conference, scheduled for January 11, 2021, at 10:00 a.m. ET. A live audio webcast of the presentation will be available on the company's website. Additionally, AtriCure will attend one-on-one investor meetings at the Needham Annual Growth Conference on January 14, 2021. The company is known for its innovative technologies, including the FDA-approved Isolator® Synergy™ Ablation System and AtriClip® devices, which are widely used in Afib treatment.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1 to 3, 2020. The company focuses on innovative technologies for Afib treatment, impacting over 33 million individuals globally. Their Isolator® Synergy™ Ablation System is the first FDA-approved device for persistent Afib treatment, while the AtriClip® Left Atrial Appendage Exclusion System is the most widely sold LAA management device. For more details, visit AtriCure's Investor Relations page.
AtriCure, Inc. (Nasdaq: ATRC) announced its third quarter 2020 results, reporting revenue of $54.8 million, a decrease of 3.3% year-over-year, largely due to the COVID-19 pandemic affecting surgical procedures. U.S. revenue fell by 3.1% to $44.7 million, while international revenue dropped 4.1% to $10.1 million. Gross profit was $40.3 million with a gross margin of 73.7%. The net loss per share improved to $0.11 from $0.25 in Q3 2019. For Q4 2020, the company expects revenue between $56 million and $60 million, with a full-year guidance of $205 million to $209 million.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in two investor conferences. The management team will present at the Stifel Healthcare Conference on November 18, 2020, at 11:20 a.m. ET, with a live webcast available on their website. Additionally, they will engage in one-on-one meetings at the Canaccord MedTech and Diagnostics Forum on November 19, 2020, without a webcast. AtriCure’s innovations are crucial in managing Afib, impacting over 33 million people globally and showcasing their FDA-approved Isolator® Synergy™ Ablation System.
AtriCure, a leader in treatments for atrial fibrillation (Afib), announced that it will release its third quarter 2020 financial results on November 5, 2020. A conference call to discuss these results will take place at 4:30 p.m. Eastern Time on the same day. AtriCure's innovative technologies, like the FDA-approved Isolator® Synergy™ Ablation System and the AtriClip® Left Atrial Appendage Exclusion System, are widely utilized by medical professionals for Afib management, affecting over 33 million people globally. For further details, visit AtriCure.com.
FAQ
What is the current stock price of Atricure (ATRC)?
What is the market cap of Atricure (ATRC)?
What does AtriCure, Inc. specialize in?
What is the Isolator® Synergy™ Ablation System?
What is AtriClip?
How does AtriCure distribute its products?
What types of products does AtriCure offer?
Where does AtriCure generate most of its revenue?
Are AtriCure’s products used internationally?
What makes AtriCure's products unique?
Where can I find more information about AtriCure?
What are AtriCure’s latest achievements?
